News|Articles|July 1, 2026

Q2 2026 Recap: Allergy News & Updates

Fact checked by: Tim Smith

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

Allergy news accelerated this quarter, with major regulatory, clinical trial, and research developments reshaping care. The US Food & Drug Administration (FDA) expanded epinephrine nasal spray (neffy) access via weight-based dosing, while phase 3 HAELO data positioned lonvoguran ziclumeran (lonvo-z) as a potential one-time CRISPR therapy for hereditary angioedema, cutting attack rates by 87%.